Resultados de Búsqueda

Evidencias COVID-19

Centro Cochrane Iberoamericano

A consortium of academic medical centers in the United States and Canada is proposing a set of recommendations for health professionals to prevent harm during the VOC-19 pandemic. The risks and benefits to both patients and health care workers of each test and treatment need to be carefully weighed.

Evidencias COVID-19

Cochrane - Revisión rápida

There are 98 ongoing studies, 50 of which are RCTs, evaluating plasma and hyperimmune immunoglobulin. This is the first update of the review, and it will continue to be updated on a regular basis. These updates may show different results than those described here.

Evidencias COVID-19

Cochrane Portugal - Institute for Evidenced Based Health

The results of this study ( J.H. Beigel et al. Remdesivir for the treatment of Covid‐19 ‐ Preliminary report. NEJM published on May 22. 2020 DOI: 10.1056/NEJMoa2007764) seem to suggest the benefit of remdesivir on Covid-19, but they are preliminary data, difficult to generalize: for example, benefits were found mostly in more severe (but not ventilated) patients and in milder patients over time. The recovery period was the same: 5 days. These overall data seem to suggest that the timing of ...

Evidencias COVID-19

Cochrane Portugal - Institute for Evidenced Based Health

The link between vitamin D and Covid-19 arises through the possibility that a population deficiency of vitamin D, to a greater or lesser extent, may be associated with a higher rate of SARS-CoV-2 infection or, alternatively, a worse diagnosis in those already infected. It is known that groups with higher infection rates may have higher levels of vitamin D deficiency, for example, the elderly and those with chronic illnesses, so this line of reasoning seems logical. But children, who are also at ...

Evidencias COVID-19

Cochrane Portugal - Institute for Evidenced Based Health

The data available so far, although not conclusive, do not allow to measure with certainty the benefit and risk of therapies with convalescent plasma or hyperimmune immunoglobulin in patients with Covid-19. We will have to wait for the results of the 22 clinical trials still in progress.